title: Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease.
abstract: Recent pharmacotherapy trials in Parkinson's disease (PD) using dopaminergic neuroimaging as outcome parameter failed to show significant relationships between imaging and clinical results. One possible explanation is that there is a non-linear relationship between striatal denervation and motor performance reflecting a statistical "floor" effect in the imaging data with advanced disease. Both the motor manifestations and the striatal dopamine denervation of idiopathic PD, however, are typically asymmetric and more meaningful associations may be found by comparing data from the least denervated striatum with motor performance in the corresponding body side. PD patients (n=28) underwent [11C]beta-CFT dopamine transporter (DAT) positron emission tomography (PET) and grooved pegboard testing. Voxel-based analysis of DAT PET and bimanual pegboard scores demonstrated significant correlation clusters within the bilateral striata (P<0.001). However, findings were most prominent in the least denervated striatum. There was a significant inverse correlation between pegboard scores of the least affected arm and DAT binding of the least denervated striatum (Rs=-0.69, P<0.0001) but no significant correlation between pegboard scores of the clinically most affected arm and DAT binding of the most denervated striatum (Rs=-0.15, ns). These data indicate that the robustness of the grooved pegboard test as a biomarker for nigrostriatal denervation in PD mainly reflects the relationship between test performance of the clinically least affected limb and the least denervated striatum. These findings indicate that there is both a statistical "floor" and "ceiling" effect for the most affected striatal and body sides that must be considered when employing imaging as an outcome measure in clinical trials in PD.
authors: Department of Radiology, University of Michigan, Ann Arbor, MI 48109-0028, USA. nbohnen@umich.edu
authors: Nicolaas I
authors: NI
authors: Bohnen
authors: Hiroto
authors: H
authors: Kuwabara
authors: Gregory M
authors: GM
authors: Constantine
authors: Chester A
authors: CA
authors: Mathis
authors: Robert Y
authors: RY
authors: Moore
mesh_terms: D000368:Aged; D015415:Biomarkers; D003042:Cocaine / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007554:Isotopes; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications* / Q000000981:diagnostic imaging / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods; D011597:Psychomotor Performance / Q000502:physiology*; D020955:Striatonigral Degeneration / Q000000981:diagnostic imaging / Q000209:etiology* / Q000473:pathology
chemical_list: D015415:Biomarkers; D007554:Isotopes; C021279:(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester; D003042:Cocaine
references: J Psychiatr Res. 1975 Nov;12(3):189-98
references: 1202204
references: Neurology. 1967 May;17(5):427-42
references: 6067254
references: N Engl J Med. 1988 Apr 7;318(14):876-80
references: 3352672
references: Mov Disord. 1990;5(3):203-13
references: 2117706
references: J Cereb Blood Flow Metab. 1991 Sep;11(5):735-44
references: 1651944
references: J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
references: 1564476
references: J Comput Assist Tomogr. 1993 Jul-Aug;17(4):536-46
references: 8331222
references: Nucl Med Biol. 1995 Feb;22(2):235-9
references: 7767319
references: Ann Neurol. 1995 Oct;38(4):589-98
references: 7574455
references: Nucl Med Biol. 1995 Nov;22(8):965-79
references: 8998473
references: Ann Neurol. 1997 Jan;41(1):58-64
references: 9005866
references: Ann Neurol. 1996 Dec;40(6):873-84
references: 9007092
references: Neuroimage. 1996 Dec;4(3 Pt 1):153-8
references: 9345505
references: Brain. 1999 Sep;122 ( Pt 9):1637-50
references: 10468504
references: Arch Neurol. 2004 Dec;61(12):1920-5
references: 15596613
references: Neurology. 2005 Jan 25;64(2):208-15
references: 15668415
references: Ann Neurol. 2006 Apr;59(4):591-6
references: 16566021
references: Expert Rev Neurother. 2006 Jun;6(6):823-31
references: 16784406
references: Mov Disord. 2006 Jul;21(7):958-63
references: 16550545
references: Brain. 2007 Jul;130(Pt 7):1834-46
references: 17470495
references: Ann Neurol. 2000 Apr;47(4):493-503
references: 10762161
references: JAMA. 2002 Jul 17;288(3):311-2; author reply 312-3
references: 12117386
references: J Cereb Blood Flow Metab. 2002 Dec;22(12):1440-52
references: 12468889
references: J Cereb Blood Flow Metab. 2003 Sep;23(9):1096-112
references: 12973026
references: Mov Disord. 2003 Oct;18 Suppl 7:S43-51
references: 14531046
references: Neuroimage. 2004;23 Suppl 1:S250-63
references: 15501095
references: Pharmacol Rev. 1966 Jun;18(2):925-64
references: 5328389
references: Annu Rev Neurosci. 1986;9:357-81
references: 3085570